GlassScriptPhysician profile
Emma Arquitola
NPI 1700308616
$12,977.00
in general payments reported to CMS, 2019-2025
61 companies · $2,054 in 2025
The $2,054 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,523 · 2022: $2,870 · 2023: $2,408 · 2024: $3,122 · 2025: $2,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,157 · Education: $260 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,157.15 |
| Education | $260.27 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,005.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $973.61 | 2021-2025 | Imfinzi, Calquence, Lynparza |
| Janssen Biotech, INC. | $726.70 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Lilly USA, LLC | $568.14 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $470.57 | 2021-2025 | |
| Seagen INC. | $457.67 | 2021-2023 | Tukysa, Padcev |
| Merck Sharp & Dohme LLC | $444.23 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $433.64 | 2021-2023 | Lumakras, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $425.15 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Incyte Corporation | $399.01 | 2021-2025 | Jakafi |
| Sobi, INC | $381.85 | 2022-2025 | |
| Eisai INC. | $326.81 | 2021-2025 | |
| Celgene Corporation | $301.05 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Astellas Pharma US INC | $286.63 | 2021-2025 | Xtandi, Padcev |
| Stemline Therapeutics INC. | $269.80 | 2023-2025 | Orserdu |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Arquitola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.